Post Profile

Watson Said to Near $6.6 Billion Deal for Actavis

Watson Pharmaceuticals is expected to bid as much as €5 billion ($6.6 billion) for the Swiss drug maker Actavis Group, in a deal that would create one of the world's largest generic drug manufacturers.
read more

See more about: Watson Pharmaceuticals

Related Posts

Watson buys Actavis Group for €4.25bn

Medical / Pharmaceutical : PharmaGossip

via Watson Pharmaceuticals has completed its acquisition of the Actavis Group for €4.25 billion to create the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues i...

Analysts Get Hooked On Watson After Actavis Deal

Business & Finance / Investing : CNBC Stock Blog

Although Watson Pharmaceuticals’ acquisition of Swiss generic drug maker Actavis was expected for over a month, a strong reaction to Wednesday’s deal shows that analysts are hooked on the drugmaker.

Watson’s Bottom Line to Get Lift From Actavis

Business & Finance : Deal Journal -

Generic drug maker Actavis is growing faster than the European sector, according to its chief executive and is set to contribute at least €2 billion ($2.6 billion) to this year's sales of U.S. based Watson Pharmaceuticals, which bou...

Watson in Talks to Buy Swiss Drugmaker Actavis - Businessweek

Medical / Pharmaceutical : PharmaGossip

Watson Pharmaceuticals Inc. (WPI) is in talks to buy Actavis Group hf, a Swiss maker of generic drugs, a person with knowledge of the matter said. Watson made an unsolicited approach to Actavis, said the person, who declined to be i...

Watson Said to Bid $5.9 Billion for Actavis

Business & Finance : DealBook

Watson Pharmaceuticals is expected to offer 4.5 billion euros ($5.9 billion) for Swiss drug maker Actavis Group on Wednesday, in a deal that would create one of the world's largest generic drug manufacturers.


Copyright © 2016 Regator, LLC